1. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. (July 2022) Authors: Harrison, Stephen A; Abdelmalek, Manal F; Neff, Guy; Gunn, Nadege; Guy, Cynthia D; Alkhouri, Naim; Bashir, Mustafa R; Freilich, Bradley; Kohli, Anita; Khazanchi, Arun; Sheikh, Muhammad Y; Leibowitz, Mark; Rinella, Mary E; Siddiqui, Mohammad S; Kipnes, Mark; Moussa, Sam E; Younes, Ziad H; Bansal, ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 7(2022) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Editorial: Age and Non‐Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?. (May 2017) Authors: Stine, Jonathan G; Rinella, Mary E Journal: American journal of gastroenterology Issue: Volume 112:Number 5(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10126 (24th March 2018) Authors: Harrison, Stephen A; Rinella, Mary E; Abdelmalek, Manal F; Trotter, James F; Paredes, Angelo H; Arnold, Hays L; Kugelmas, Marcelo; Bashir, Mustafa R; Jaros, Mark J; Ling, Lei; Rossi, Stephen J; DePaoli, Alex M; Loomba, Rohit Journal: Lancet Issue: Volume 391:Issue 10126(2018) Page Start: 1174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗